Print this page    •   Back to Web version of article

Medical News
Microbicide Trials Network Stops Tenofovir Arm of Study After Findings Show Drug Less Effective Than Anticipated

September 29, 2011

"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, [on Wednesday] announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board ... found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports. "Although the board did not offer any specifics on how many women became infected on the drug versus placebo, they said continuing with the tenofovir arm was 'futile' as it would not yield meaningful results," the blog writes.

"The new results particularly baffled people who follow this promising prevention strategy because there were mixed but encouraging findings in two similar studies reported earlier this year," the blog writes, adding that Sharon Hillier, who heads the MTN, "emphasizes that these conflicting findings underscore that much remains to be learned about PrEP." Additional research analyzing why the drug would work to decrease HIV infection in one population and not another needs to be conducted, the blog notes. The Vaginal and Oral Interventions to Control the Epidemic (VOICE) study, which began in September 2009, includes two other arms testing a tenofovir vaginal gel and the combination antiretroviral drug Truvada and "is not scheduled to end until about one year from now," according to the blog (Cohen, 9/28).

Back to other news for September 2011

This information was reprinted from with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.